Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSBR-1290 PK and safety study in healthy overweight/obese participants
NCT06139055Phase 1Active, not recruiting
- Sponsor
- Gasherbrum Bio
- Start
- Oct 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aleniglipron in obesity and Overweight (5 arms), sponsored by Gasherbrum Bio. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Time to Maximum Observed Plasma Concentration at Day 10 and 9 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
aleniglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06139055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139055.